Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01010750 · ClinicalTrials.gov registry record · Phase 1

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

A Phase 1 study of Attention Deficit Hyperactivity Disorder, sponsored by Shire.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT01010750 is a Phase 1 study of Attention Deficit Hyperactivity Disorder that has completed, run by Shire. The registered enrollment target is 18 participants, below the 207-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01010750, a Phase 1 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

To evaluate the sensitivity and responsiveness of a standardized, validated, computer-based, battery of neuro-psychometric tests in adults with ADHD.

Interventions

  • DRUG Lisdexamfetamine Dimesylate (LDX)
  • DRUG Immediate Release Mixed Amphetamine Salts (MAS-IR)
  • DRUG LDX Placebo + MAS-IR Placebo

Study Locations (1)

Texas

  • Claghorn-Lesem Research Clinic - Houston

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2010-01-05
Est. Completion 2010-03-28
Phase Phase 1

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT01010750

The ClinicalTrials.gov registry entry for NCT01010750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 3 interventions - of which Lisdexamfetamine Dimesylate (LDX) is the first listed.

NCT01010750 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01010750 about?

NCT01010750 is a clinical study titled "Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)". To evaluate the sensitivity and responsiveness of a standardized, validated, computer-based, battery of neuro-psychometric tests in adults with ADHD.

What is the current status of trial NCT01010750?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-01-05. Estimated completion is 2010-03-28.

What conditions does trial NCT01010750 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT01010750?

The interventions under investigation include: Lisdexamfetamine Dimesylate (LDX) (DRUG), Immediate Release Mixed Amphetamine Salts (MAS-IR) (DRUG), LDX Placebo + MAS-IR Placebo (DRUG).

Who is sponsoring clinical trial NCT01010750?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01010750 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.